<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) are <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> disorders in which conflicting results in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and multidrug resistance (<z:chebi fb="14" ids="53218">MDR</z:chebi>) have been reported </plain></SENT>
<SENT sid="1" pm="."><plain>We have evaluated by multiparameter flow cytometry the expression of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>- (APO2.7, bcl-2, and bax) and <z:chebi fb="14" ids="53218">MDR</z:chebi>-related proteins [P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (P-gp), multidrug resistance protein (MRP), and lung resistance protein (LRP)] specifically on bone marrow (BM) CD34+ cells, and their major CD32-/dim and CD32+ subsets, in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (n=90), high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n=9), and low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n=21) patients at diagnosis, and compared with <z:mpath ids='MPATH_458'>normal</z:mpath> BM CD34+ cells (n=6) </plain></SENT>
<SENT sid="2" pm="."><plain>CD34+ myeloid cells from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> patients displayed higher expression of bcl-2 (P &lt;0.0001) and lower reactivity for APO2.7 (P=0.002) compared with low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="3" pm="."><plain>Similar results applied to the two predefined CD34+ myeloid cell subsets </plain></SENT>
<SENT sid="4" pm="."><plain>No significant differences were found in the expression of P-gp, MRP, and LRP between low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> patients and <z:mpath ids='MPATH_458'>normal</z:mpath> BM, but decreased expression of MRP (P &lt;0.03) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and P-gp (P=0.008) in high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> were detected </plain></SENT>
<SENT sid="5" pm="."><plain>Hierarchical clustering analysis showed that low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> patients were clustered next to <z:mpath ids='MPATH_458'>normal</z:mpath> BM samples, whereas high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> were clustered together and mixed with the de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="6" pm="."><plain>In summary, increased resistance to chemotherapy of CD34+ cells from both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> would be explained more appropriately in terms of an increased antiapoptotic phenotype rather than a <z:chebi fb="14" ids="53218">MDR</z:chebi> phenotype </plain></SENT>
<SENT sid="7" pm="."><plain>In low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> abnormally high apoptotic rates would be restricted to the CD34- cell compartments </plain></SENT>
</text></document>